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Abstract 
Recent studies of transgenic mice and humans have provided compelling evidence for 
the importance of the hypothalamic melanocortin system in the regulation of energy 
balance. Energy homeostasis is a balance between food intake (energy input) and 
energy expenditure. The melanocortin system regulates feeding via effects of the 
endogenous agonist, α-melanocyte stimulating hormone (α-MSH) and the endogenous 
antagonist agouti-related protein (AgRP) on melanocortin 3 and 4 receptors (MC3-Rs 
and MC4-Rs). It has been demonstrated that the melanocortin system interacts with 
the hypothalamo-pituitary-thyroid (HPT) axis. Thyroid hormones influence 
metabolism and hence energy expenditure. Therefore, an interaction between the HPT 
axis and the melanocortin system would allow control of both sides of the energy 
balance equation, by the regulation of both energy input and energy expenditure. Here 
we will discuss the evidence demonstrating interactions between the melanocortin 
system and the HPT axis. 
 
1. Introduction 
There is growing evidence that the central melanocortin system is important in the 
regulation of energy balance through co-ordinated actions on both food intake and 
energy expenditure [58]. Within this system, agouti-related protein (AgRP), the 
endogenous antagonist at melanocortin 3 and 4 receptors (MC3- and MC4-Rs), 
stimulates feeding [50;53], whereas alpha-melanocyte stimulating hormone (α-MSH), 
the endogenous ligand for these receptors, reduces food intake. The α-MSH precursor, 
pro-opiomelanocortin (POMC), is expressed in a population of arcuate neurons 
distinct from those expressing AgRP. 
 
Energy homeostasis is a balance between food intake (energy input) and energy 
expenditure [22]. The hypothalamo-pituitary-thyroid (HPT) axis produces the thyroid 
hormones tri-iodothyronine (T3) and thyroxine (T4), which stimulate energy 
expenditure, largely via increased thermogenesis [59]. Therefore, the HPT axis plays 
a key role in the regulation of energy homeostasis. Whilst initial studies of the role of 
the melanocortin system in the regulation of energy homeostasis concentrated largely 
on the control of food intake, more recent studies have also shown an interaction 
between the melanocortin system and the HPT axis. Such an interaction would allow 
control of both sides of the energy balance equation, by the regulation of both energy 
input and energy expenditure. Here we will discuss the evidence demonstrating 
interactions between the melanocortin system and the HPT axis. 
 
2. The HPT axis 
The hypothalamic tri-peptide, thyrotrophin-releasing hormone (TRH), is essential for 
the normal biosynthesis and release of thyroid stimulating hormone (TSH) from the 
anterior pituitary and in turn, thyroid hormones from the thyroid gland [65]. Although 
TRH neurons are located in a number of hypothalamic nuclei [38], the 
hypophysiotrophic TRH neurons which project to the median eminence to regulate 
anterior pituitary TSH release are confined to the medial and periventricular 
parvocellular regions of the PVN [29]. TRH is released from these hypophysiotrophic 
neurons into the hypophyseal portal circulation to regulate the release of TSH from 
the anterior pituitary. TSH stimulates the thyroid gland to synthesise and release the 
thyroid hormones T4 and the biologically more active T3. The major pathway for the 
production of T3 is via 5’-deiodination of the outer ring of T4 by deiodinase enzymes 
which accounts for the majority of circulating T3 [68]. When plasma thyroid hormone 
concentrations fall, such as in primary hypothyroidism, TRH biosynthesis and 
secretion are up-regulated in hypophysiotrophic TRH neurons, thus increasing TSH 
release from thyrotrophs in the anterior pituitary [63]. 
 
3. The HPT axis and starvation 
It has been well characterised that in states of negative energy balance, such as 
prolonged fasting, regulation of the HPT axis is altered, as manifested by low plasma 
T3, and T4, with a low or inappropriately normal TSH and a reduction in TRH 
biosynthesis and secretion [1,5,9,15,16,25,27,33,51,64]. This central hypothyroidism 
following starvation may be an important adaptive response, by reducing 
thermogenesis and hence, reducing the obligatory use of energy stores [21]. Present 
evidence indicates that this adaptation to starvation is achieved through a reduction in 
PVN TRH, demonstrating that a central mechanism contributes to this physiological 
adaptive response. Starvation specifically down-regulates TRH mRNA expression in 
the PVN where hypophysiotrophic TRH neurons are located [5]. This effect of 
starvation is specific to the PVN, since adjacent non-hypophysiotrophic TRH neurons 
in the lateral hypothalamus are unaffected by fasting [40]. 
 
4. Leptin and the HPT axis 
Following the discovery of the adipocyte-derived hormone leptin by Friedman et al in 
1994 [69], subsequent studies over the last decade support a role for leptin as a 
negative feedback signal from the periphery to the central nervous system (CNS) to 
regulate energy homeostasis (for reviews see [17], 44 ,58]. In addition to its role in 
regulating body weight, leptin signals to the CNS the transition from the fed to fasted 
state (for review see [70]).  
 In rodents, peripheral administration of leptin during a forty-eight hour fast 
substantially blunts the observed fasting-induced fall in plasma T4 [1 40]. Leptin 
appears to be acting at the level of the hypothalamus, since exogenous leptin 
abrogates the fasting-induced suppression of pro-TRH mRNA [40]. Regulation of the 
HPT axis by leptin may be direct through the long form of its receptor Ob-R, which is 
present on a subset of TRH neurons in the PVN or indirect, via its actions on the 
arcuate nucleus [26, 49]. In support of a direct role, leptin directly activates the TRH 
promoter in vitro [26] and in vivo [24] via the signal transducer and activator of 
transcription 3 (STAT 3) signalling pathway. However, because there is a high 
concentration of Ob-Rs in the arcuate nucleus [3] and chemical ablation of the arcuate 
nucleus abolishes the effect of fasting and leptin administration on the HPT axis [41], 
leptin may also indirectly regulate the HPT axis via the arcuate nucleus.  
 
5. The melanocortin system and the HPT axis 
Leptin activates POMC gene expression in the arcuate nucleus [46 62] making 
POMC-derived α-MSH a candidate for mediating the indirect regulation of TRH 
expression by leptin. Several rodent studies using double-labelling 
immunocytochemistry show that the melanocortin system is well positioned to 
interact with the HPT axis. Arcuate α-MSH neurons send monosynaptic projections to 
the soma and first-order dendrites of TRH neurons in the parvocellular division of 
PVN, the site of hypophysiotrophic TRH neurons [19]. In addition, AgRP is also 
contained in axon terminals heavily innervating TRH neurons in the PVN [42]. In 
fact, all TRH neurons receiving contacts from α-MSH containing fibres are also 
innervated by axons containing AgRP [19]. These findings have been replicated in 
humans, with the demonstration that α-MSH- and AgRP-containing neurons within 
the infundibular nucleus, the human equivalent of the rodent arcuate nucleus, are in 
close juxtaposition to PVN TRH neurons [45]. Since both α-MSH and AgRP signal 
through the MC4-R, the finding that approximately half of TRH neurons in the medial 
parvocellular PVN express the MC4-R [26] provides further morphological evidence 
to support a role for the melanocortin system in the response of the HPT axis to 
altered energy states. 
 
Recent in vitro and in vivo studies provide further support for this hypothesis. 
Intracerebroventricular (ICV) infusion of α-MSH in fasted rats completely restores 
pro-TRH mRNA levels in the PVN to normal fed levels [19]. Arcuate AgRP mRNA 
expression in the same group of rats remained elevated despite α-MSH 
administration, indicating that this positive effect of exogenous α-MSH on PVN pro-
TRH mRNA is not due to an inhibition of AgRP gene expression [19]. However, in 
the same study, plasma thyroid hormones were only restored to 50% of fed levels by 
ICV α-MSH. This is in contrast to the effects of exogenous leptin administration 
during fasting, which restores both pro-TRH mRNA in the PVN and plasma thyroid 
hormones to fed levels [40]. Therefore, it appears that α-MSH mediates only some of 
the regulatory effects of leptin on the HPT axis. Consistent with a stimulatory effect 
of α-MSH on the HPT axis, a single ICV injection of α-MSH in fasted rats increases 
plasma TSH and stimulates TRH release from hypothalamic explants [32].  
 
The MC4-R, like the other MC-Rs, signals by increasing levels of intracellular cyclic 
AMP (cAMP) [66]. This in turn activates protein kinase A and hence, phosphorylates 
cAMP response element binding protein (CREB), to induce the transcription of genes 
containing a cAMP response element (CRE) [14]. Human, rat and murine TRH 
promoters have a conserved element that bears close homology to a canonical CRE 
[39]. In vitro studies in a heterologous cell system demonstrate that α-MSH signalling 
through MC4-Rs activates the TRH promoter via phosphorylation and binding of 
CREB [26]. This was recapitulated in vivo where ICV injection of α-MSH increased 
phosphorylated CREB in TRH neurons within the anterior, medial and periventricular 
parvocellular subdivisions of the PVN [56].  
 
Conversely, CNS infusion of AgRP to ad libitum fed rats produces central 
hypothyroidism, with reduced plasma thyroid hormones, inappropriately normal or 
decreased TSH and suppressed PVN pro-TRH mRNA expression [20, 60]. However, 
CNS administration of AgRP did not affect type 2 deiodinase activity in brown 
adipose tissue (BAT), a major effector organ for thyroid hormones in regulating 
thermogenesis [20]. This finding, together with a marked reduction in pro-TRH 
mRNA expression in the PVN, suggests that AgRP acts centrally, via TRH 
suppression within the PVN, rather than peripherally to reduce circulating thyroid 
hormones. In support of this, AgRP inhibits TRH release in vitro from hypothalamic 
explants [32]. Furthermore, AgRP [32] and the synthetic MC4-R antagonist SHU9119 
[49] inhibit leptin-induced hypothalamic TRH release in vitro.  
 
Together, these data provide support a role for α-MSH and AgRP mediating the 
effects of leptin on the HPT axis via central melanocortin receptors. Further work is 
needed to establish whether additional peripheral hormones regulating energy balance 
can also influence the HPT axis via the melanocortin system. Although both MC3- 
and MC4-Rs are abundant in the hypothalamus [47, 52], it remains unclear which 
receptor is the key regulator of energy balance. The obesity phenotype of the MC4-R 
null mouse strongly supports a role for this receptor in obese states [28]. Transgenic 
mice lacking the MC3-R have not clarified the role of the MC3-R to the same extent 
[7, 13]. Similarly, since α-MSH [57] and AgRP [50] bind to both MC3- and MC4-Rs, 
studies of the interactions between the melanocortin system and the HPT axis are 
unable to establish which receptor subtype(s) is involved. An in vitro study using 
selective MC3- and MC4-R ligands has suggested differential roles for the MC3- and 
MC4-Rs in the regulation of hypothalamic TRH release [31]. However, to date, only 
the MC4-R has been found to be expressed on TRH neurons [26]. Therefore, the exact 
role of the MC3- and MC4-R in the regulation of the HPT axis needs further 
clarification. 
 
6. Thermogenesis, thyroid hormones and the melanocortin system 
Thermogenesis involves the production of heat to maintain body temperature in cold 
environments. Thermogenic mechanisms are classified as either obligatory or 
adaptive. Obligatory thermogenesis represents the energy dissipated as heat in the 
many energetic transformations inherent to life. Diet-induced thermogenesis is a form 
of adaptive thermogenesis and describes the marked increase in heat production 
which serves to reduce or prevent the development of obesity [55]. In small 
mammals, including the human neonate, the main site of adaptive thermogenesis is 
BAT. The remarkable thermogenic capacity of BAT is due to its unique ability to 
uncouple phosphorylation in a controlled manner, allowing it to dissipate energy as 
heat [55].  
 
The primary molecule involved in adaptive thermogenesis in BAT is uncoupling 
protein (UCP-1), which is organised in the inner membrane of BAT mitochondria and 
uncouples proton entry from ATP synthesis [34, 48]. UCP-1 is exclusive to BAT 
where it is regulated by the sympathetic nervous system and peripheral hormonal 
factors including thyroid hormones [30]. Both cold exposure [4] and hyperphagia [12] 
are associated with an increase in BAT UCP-1 levels. Intracellular conversion of T4 
to T3 by type 2 deiodinase is essential for the typical cold-induced increase in BAT 
UCP protein [6]. However diet-induced thermogenesis may not be associated with 
altered BAT type 2 deiodinase activity [35]. Nevertheless, thyroid hormones do 
potentiate diet-induced thermogenesis [54].  
 
In addition to its role in regulating food intake, the central melanocortin system may 
regulate thermogenesis in BAT and hence, energy expenditure. A single ICV injection 
of α-MSH increases BAT temperature and BAT sympathetic nerve activity, whereas 
conversely, these are decreased by AgRP [67]. Similarly, prolonged ICV 
administration of the synthetic MC4-R antagonist HS014 suppresses BAT UCP-1 
mRNA levels [2], yet chronic peripheral injection of the MC4-R agonist MTII is 
associated with an increase [10].  
 
In support of these findings, MC4-R null mice are unable to increase oxygen 
consumption, a marker of energy expenditure, in response to high-fat diet suggesting 
that the MC4-R is necessary for diet-induced thermogenesis [8]. Similarly, MC4-R 
null mice are also unable to increase activity-based energy expenditure, shown to 
make an important contribution to energy balance [43], following increases in dietary 
fat [8].  
 Regulation of adaptive thermogenesis by the melanocortin system may be achieved, at 
least in part, via the HPT axis. In rodents, chronic AgRP injection increases BAT 
weight due to increased adiposity, but reduces BAT UCP-I protein and plasma TSH 
[60]. Interestingly, these effects are independent of food intake. Similarly, chronic 
ICV administration of AgRP over the same period reduces oxygen consumption as a 
marker of energy expenditure, associated with blunted BAT thermogenic capacity 
[61]. Therefore, inhibition of the HPT axis by AgRP may down-regulate BAT UCP-I 
levels, hence reducing adaptive thermogenesis and ultimately, energy expenditure.  
 
7. The HPT axis in models of an abnormal melanocortin system 
A number of transgenic murine models of abnormal melanocortin signalling have 
provided considerable support for the importance of the melanocortin system in 
regulating energy balance. However, to date, detailed analyses of the HPT axis in 
these models are limited. MC3-R deficient mice have normal plasma T4 levels [7, 
13], although plasma thyroid hormones in either MC4-R-null [28] or AgRP over-
expressing [23, 50] have not been described. In a recent study, transgenic mice 
lacking all POMC-derived peptides had reduced plasma T4 [11], consistent with a 
stimulatory effect of POMC-derived peptides such as α-MSH on the HPT axis. 
 
In humans, MC4-R mutations are the commonest monogenic form of obesity [18]. 
Although the majority of individuals with MC4-R deficiency have plasma T4 and 
TSH levels within the normal range, a small number have an elevation in plasma TSH 
[18]. Since the normal range for plasma T4 is wide, this does not exclude 
abnormalities in the HPT axis of these individuals, particularly under circumstances 
such as fasting which may functionally challenge the HPT axis. Humans deficient in 
POMC are hyperphagic and obese, with red hair [36]. In the original study describing 
these individuals, it was assumed that their HPT axis was normal due to normal 
plasma T4 [36]. However, a recent, more detailed analysis of these subjects shows 
that in fact POMC-deficient humans have normal plasma T3 and T4 levels, with 
elevated plasma TSH which can be suppressed to within the normal range with T4 
supplementation [37]. The mechanism responsible for these abnormalities remains 
under investigation, but does provide further support for stimulatory effects of 
melanocortin peptides such as α-MSH on the HPT axis. 
 
8. Conclusions 
The role of the melanocortin system is well established in the regulation of food 
intake. However, it is becoming increasingly clear that there is an additional important 
role for the melanocortin system in the regulation of energy expenditure, at least in 
part, due to interactions with the HPT axis. Anatomically, POMC and AgRP neurons 
are poised to regulate hypophysiotrophic neurons in the PVN. Growing evidence 
supports a stimulatory role for α-MSH on the HPT axis, whilst AgRP is inhibitory. 
The interaction between the HPT axis and the melanocortin system is shown 
schematically in Figure 1. In states of negative energy balance, associated with an 
increase in AgRP, valuable energy stores would be conserved by both an increase in 
food intake and a reduction in energy expenditure, in part due to suppression of the 
HPT axis. Conversely, in times of nutritional abundance, an associated increase in α-
MSH would serve to signal both a reduction in food intake and also an increase in 
energy expenditure by up-regulating the HPT axis. These alterations in energy 
expenditure as well as food intake may be important adaptive responses in 
maintaining energy homeostasis. Although the adiposity signal leptin is likely to also 
have direct effects on the HPT axis, it seems likely that some of these effects may be 
mediated indirectly via the melanocortin system. However, further work is needed to 
establish whether the melanocortin system regulates the HPT axis independently of 
leptin and this remains a fascinating area for further investigation. 
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Figure legend 
Figure 1 
A hypothetical model of the interactions between the melanocortin system and the 
HPT axis in fed and fasted animals. In the fed state (shown on the right), an elevation 
in circulating leptin promotes high POMC and low AgRP mRNA levels in the arcuate 
nucleus, with subsequent increased MC4-R activation. This is associated with a 
reduction in food intake and an increase in the activity of the HPT axis, stimulating 
energy expenditure. In the fasted state (shown on the left), circulating leptin falls, 
leading to a reduction in POMC and an increase in AgRP mRNA expression in the 
arcuate nucleus. In this state of negative energy balance, increased AgRP stimulates 
food intake and inhibits the HPT axis, reducing energy expenditure. Although the 
melanocortin system may mediate some of the effects of leptin on the HPT axis, 
leptin also has direct effects on the TRH neurons in the hypothalamic PVN (shown by 
dashed arrows).  
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